HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis

A 73-year-old man presented with multiple lymphadenopathy. He had a 20-year history of palmoplantar psoriasis evolved to a diffuse erythrodermic picture in the last two years. Topic and systemic medications including prednisolone, acitretin, anti-IL17 (ixekizumab), TNF inhibitor (adalimumab), anti-IL23 (guselkumab), methotrexate, cyclosporine, and phosphodiesterase 4 inhibitor (apremilast) were ineffective. Repeated skin biopsies excluded mycosis fungoides, confirming psoriasis; molecular analysis of T-cell receptor genes ruled out clonality. The axillary lymph node histology documented a dermatopathic lymphadenitis, often associated with chronic cutaneous inflammatory diseases. At an accurate morphological evaluation, features of HHV8-positive multicentric Castleman disease were observed. Moreover, in a few follicles, in situ mantle cell neoplasia was identified. The translocation t(11;14)(q13;q32), characteristic of mantle cell lymphoma, and the monoclonal IGH gene rearrangement were present. HHV8 DNA was identified on plasma sample. Multicentric Castleman disease in psoriatic patients is a rare event and it might be favored by the immunomodulatory treatment in longstanding psoriasis. Multicentric Castleman disease patients are predisposed to developing simultaneous or subsequent lymphoma. In situ mantle cell neoplasia often behaves indolently, although it may progress to overt mantle cell lymphoma. Rituximab achieved a good control of psoriasis. Unfortunately, the patient developed Staphylococcus aureus sepsis for which he is currently on antibiotic therapy.

The excised axillary lymph node showed distinctive reactive features of dermatopathic lymphadenitis with paracortical hyperplasia and melanin-pigmented macrophages ( Figure 2), typically seen in chronic cutaneous inflammatory diseases.       These findings were consistent with HHV8-positive multicentric Castleman disease (MCD) of mixed type associated with in situ mantle cell neoplasia (isMCN). The translocation t(11;14)(q13;q32) characteristic of mantle cell lymphoma (MCL) and the monoclonal IGH gene rearrangement were identified by fluorescence in situ hybridization (FISH) analysis and molecular study, respectively. HHV8 DNA (71 copies/mL) was identified by polymerase chain reaction (PCR) on the plasma sample. These findings were consistent with HHV8-positive multicentric Castleman disease (MCD) of mixed type associated with in situ mantle cell neoplasia (isMCN). The translocation t(11;14)(q13;q32) characteristic of mantle cell lymphoma (MCL) and the monoclonal IGH gene rearrangement were identified by fluorescence in situ hybridization (FISH) analysis and molecular study, respectively. HHV8 DNA (71 copies/mL) was identified by polymerase chain reaction (PCR) on the plasma sample.
The patient received infusions of the monoclonal antibody rituximab (375 mg/m 2 , once every two weeks x four doses). Rituximab is also reported to be helpful in treating MCD [1]. The treatment was completed about a month before our case description, achieving good control of his psoriasis. Unfortunately, the patient developed Staphylococcus aureus sepsis, for which he is currently on antibiotic treatment.
MCD commonly occurs in immunosuppressed patients, being often reported in association with HIV infection, but it may also develop in HIV-negative individuals, especially originating from HHV8-endemic regions [1]. MCD is usually negative for Epstein Barr virus, whereas it is strongly associated with Human Herpes virus 8 (HHV8) infection, detected in almost all HIV-positive cases and in 50% of HIV-negative ones [1].
In patients with psoriasis, HHV8-positive MCD is very rarely reported [6]. Its emergence has been supposed to be linked to the immunomodulatory treatment, particularly in severe and longstanding psoriasis [6]. It is worth mentioning the relevance of discussing with the patient about possible risks and benefits of the immunomodulatory treatment, as it was adequately done in the present case.
MCD patients have an increased risk of developing simultaneous or subsequent lymphomas of different subtypes, which generally follow an aggressive course [1,[7][8][9]. The patient received infusions of the monoclonal antibody rituximab (375 mg/m 2 , once every two weeks x four doses). Rituximab is also reported to be helpful in treating MCD [1]. The treatment was completed about a month before our case description, achieving good control of his psoriasis. Unfortunately, the patient developed Staphylococcus aureus sepsis, for which he is currently on antibiotic treatment.
MCD commonly occurs in immunosuppressed patients, being often reported in association with HIV infection, but it may also develop in HIV-negative individuals, especially originating from HHV8-endemic regions [1]. MCD is usually negative for Epstein Barr virus, whereas it is strongly associated with Human Herpes virus 8 (HHV8) infection, detected in almost all HIV-positive cases and in 50% of HIV-negative ones [1].
In patients with psoriasis, HHV8-positive MCD is very rarely reported [6]. Its emergence has been supposed to be linked to the immunomodulatory treatment, particularly in severe and longstanding psoriasis [6]. It is worth mentioning the relevance of discussing with the patient about possible risks and benefits of the immunomodulatory treatment, as it was adequately done in the present case.
MCD patients have an increased risk of developing simultaneous or subsequent lymphomas of different subtypes, which generally follow an aggressive course [1,[7][8][9].
MCL is a non-Hodgkin B-cell lymphoma, traditionally considered an aggressive disease, although more indolent forms, including isMCN, are currently well known [1].
isMCN represents a rare event, usually identified incidentally. It generally follows an indolent course, although it may rarely progress to overt MCL after many years [1].
isMCN has been exceptionally reported in association with Castleman disease [10].